DRREDDY Share Price, Analysis & Fundamentals

Despite recent gains, Dr Reddy's faces significant profit declines and mixed analyst sentiment, with institutional holdings slightly reduced ahead of upcoming Q1 FY27 results.

The market is experiencing a short-term decline with weak momentum and bearish technical indicators, despite some signs of accumulation.
The company's latest quarterly results show a significant decrease in revenue, net profit, and EPS both quarter-on-quarter and year-on-year.
Analysts provide a mixed distribution of ratings, with a slight decrease in 'Strong Buy' and an increase in 'Hold' ratings over the past month.
Institutional investors hold a majority stake, but there has been a notable decrease in FII and overall institutional holdings QoQ, offset by a slight increase in DII holdings.
The company is scheduled to announce its Q1 FY27 results on July 22, 2026.

The market is experiencing a short-term decline, with a 1-day return of 0.991% but a 5-day return of -0.915%.
Technical indicators suggest a bearish trend, with the trend alignment score at -3 and the MACD line below the signal line.
Momentum is weak, as indicated by an RSI of 35.62, which is in the lower percentile of its 1-year range.
Volume analysis shows that the current average daily volume is below the 20-day average, but there is accumulation occurring.
Valuation metrics indicate that the current P/E ratio is above its 6-month average, while the P/B ratio is slightly below its 6-month average.

The market is currently in a bearish trend, characterized by negative short-term returns, weak momentum, and a bearish technical outlook. While volume shows signs of accumulation, the overall sentiment is cautious. Valuation metrics present a mixed picture, with a high P/E ratio suggesting potential overvaluation, while the P/B ratio is more moderate. Investors should monitor key support and resistance levels and look for confirmation of a trend reversal before considering significant positions.

Latest quarter revenue at ₹7,546 Cr, with net profit at ₹221 Cr and EPS at ₹2.65.
Quarter-on-quarter, revenue decreased by -13.79%, net profit by -81.429%, and EPS by -81.724%.
Year-on-year, revenue saw a decline of -11.515%, net profit dropped by -86.074%, and EPS fell by -86.118%.
Profitability has shown a significant downward trend both quarterly and annually.

Dr. Reddy's Laboratories will announce its Q1 FY27 results on July 22, 2026, with an earnings call scheduled for 19:30 IST. The company also released a conference call transcript on July 15, 2026, as per SEBI regulations.